ClinicalTrials.gg

Respiratory Syncytial Virus Infections clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 306 studies for Respiratory Syncytial Virus Infections across more than 10 countries. 49 are recruiting or about to start. 273 of them are mainly about Respiratory Syncytial Virus Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Status

Completed
200
Recruiting
29
Terminated
22
Active, not recruiting
19
Not yet recruiting
17
Status unknown
9

Phase

Phase 1
107
Phase 2
81
Phase 3
47
Phase 4
3

Where

United States
145
United Kingdom
53
Australia
44
Spain
39
France
31
China
30

Who develops what

Add Respiratory Syncytial Virus Infections to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 22 programs from 12 companies, 22 with this as their studies’ main aim; 3 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Sanofi, GlaxoSmithKline and Enanta Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
SCB-1019TRecent, limited
Evidence
  • NCT06984094 · Clover Biopharmaceuticals AUS Pty · Phase 2 · live · comparator · “SCB-1019T” · registered May 2025
—11 study
Influenza VaccinesRecent, limited
Evidence
  • NCT05568797 · GlaxoSmithKline · Phase 3 · background · “FLU vaccine” · registered Oct 2022
—11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
abrysvo☆ Track1 live phase-3 study: NCT06866405Pfizer
ziresovir☆ Track1 live phase-3 study: NCT07658534Shanghai Ark Biopharmaceutical Co., Ltd.
arexvy☆ Track3 live phase-3 studies: NCT07220109, NCT06534892, NCT04732871GlaxoSmithKline

The 3 in phase 3 with the nearest primary completion, of 22 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.zelicapavir · Enanta Pharmaceuticals, Inc · Phase 2 main aimNCT07482657 A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus — primary endpoint: Time to complete resolution of clinical signs of RSV as measured by RESOLVE-P · 150 enrolled
  • 30 Dec 2026 est.S-337395 · Shionogi · Phase 2 main aimNCT07214571 A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease — primary endpoint: Change From Baseline in RSV Ribonucleic Acid (RNA) Load by Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) (Nasopharyngeal Swab) at Day 2 · 192 enrolled
  • 12 Jan 2027 est.Adjuvanted RSVPreF3 vaccine · GlaxoSmithKline · Phase 2 main aimNCT07092865 A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant — primary endpoint: RSV-A neutralizing titers expressed as Geometric mean titers (GMTs) · 168 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Respiratory Syncytial Virus Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

23studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger. 13 (45%) take children under 18. 2 (7%) are for women only and 0 (0%) for men only; 8 (28%) take healthy volunteers.

Recruiting studies that take each age, of 29
AgeWomenMen
103 (10%)3 (10%)
1817 (59%)15 (52%)
3017 (59%)15 (52%)
4017 (59%)15 (52%)
5016 (55%)14 (48%)
6518 (62%)17 (59%)
7518 (62%)17 (59%)
8517 (59%)16 (55%)

Across all 306 studies, recruiting or not: 66% stop at 75 or younger and 62% at 65; 44% take children; 7% are for women only and 3% for men only; 59% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Respiratory Syncytial Virus Infections studies take

Of 57 phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 18 mo5–17 · 57 studies6 mo3–12 · 44 studies—
Phase 1/222 mo9–27 · 16 studies——
Phase 211 mo5–27 · 37 studies11 mo5–27 · 32 studies—
Phase 38 mo6–23 · 32 studies8 mo4–19 · 27 studies—
Observational25 mo11–51 · 31 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 20, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 306. Browse all 306 → or search them.